As more research emerges surrounding the standardization of tumor mutational burden (TMB) assessment, a universal definition of “high TMB” across cancer types does not appear to be feasible.
Check out this recent article published in Genes, Chromosomes & Cancer on how QIAGEN is collaborating with leading institutions in cancer research and treatment to harmonize TMB estimation and reporting in clinical samples.
Read the full article here!
